Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07780656) titled 'A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)' on Aug. 19.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: GlaxoSmithKline
Condition:
Pulmonary Disease, Chronic Obstructive
Intervention:
Drug: GSK5784283
Drug: Placebo
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 31, 202...